SAFE Drugs Act of 2026
Compounding Pharmacies: New Safety and Reporting Rules
Legislative Progress
Key Points
- This bill limits how often pharmacies can make 'copycat' versions of drugs that are already sold by major manufacturers. Pharmacies would be restricted to making these copies no more than 20 times a month unless a doctor confirms a specific patient has a unique medical need for a custom version.
- Pharmacies that ship custom-mixed drugs to patients in other states more than 20 times a month must start filing annual reports with the government. These reports must list exactly what drugs they are making and how many they produce each month.
- The bill creates stricter rules for 'large-scale' facilities that make more than 100 drug products a year. These businesses would be required to pass a safety inspection before they can start making drugs and must be reinspected at least every two years.
- To pay for these new safety checks, the bill changes the fees these facilities pay to the government. Instead of a flat $15,000 fee, the government will set a price that covers the full cost of keeping these drug-making sites safe for the public.
- These changes are designed to make sure pharmacies don't act like mass-production factories without following the same strict safety standards as large drug companies. Most of these new rules would go into effect six months after the bill becomes law.
Impact Analysis
Govbase has not yet run an impact analysis on this legislation.
Milestones
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in Senate
The bill was officially filed and given a number. It now enters the legislative queue.
Votes
No votes have been recorded for this legislation yet.
Related News
5 articles
GLP-1 fight plays out in statehouses, courthouses
U.S. Sens. Jim Banks and Martin Heinrich co-sponsored the SAFE Drugs Act this month to curb mass-production of compounded 'copycat' drugs. The bill clarifies definitions of 'essentially a copy' and sets a monthly limit on units produced by pharmacies without specific medical necessity.

Novo’s GLP-1 Patent Suit Against Hims Takes Aim at Compounding
Novo Nordisk's lawsuit against Hims & Hers marks a new phase in the battle over compounded weight-loss drugs. The legal pressure coincides with the introduction of the SAFE Drugs Act, which aims to tighten federal oversight and restrict the mass-marketing of unapproved drug versions.

Compounded weight-loss drugs hit on every side
Sens. Banks and Heinrich introduced the SAFE Drugs Act to close loopholes in the FDCA. The bill would limit 503A pharmacies to 20 'essential copies' per month and require large-scale outsourcing facilities to undergo mandatory FDA inspections before starting production.
Source Information
Document Type
Congressional Bill
Official Title
SAFE Drugs Act of 2026
Data Sources
Sponsor
Cosponsors
(1)Analysis generated by AI. Always verify with official sources.